Immuno-metabolism

Driving development of our lead candidate and novel small molecule platform that acts as a "glucose rheostat". We believe robust glucose control is the key to treating disease states. We are committed to enable better long term treatment options for patients.

We are advancing a broad pipeline of biologic drug candidates. Our vast library of Novel potent and selective GPCR agonists was discovered and optimized in-house....by a team that has discovered many important drugs.

The Market

Untapped Opportunity

The opportunity for an oral treatment for Latent Autoimmune Disease in Adults that also addresses Hypoglycemia is just one of many areas of high unmet medical need associated with Immuno-metabolic disorders.

Pipeline

Improving lives targeting GPCRs

Pramana’s Lead Compound, PRM914 activates a

differentiated immune response to enable breakthrough treatments for indications associated with metabolic dysregulation.

The Team

Driving Success

HARNESSING THE POWER OF GPCRS

A Novel Approach to Therapeutic Development for Immuno-Metabolic Disorders

EXPLORE>

490,000,000,000

Dollars in Global Healthcare Expenditures of Diabetes by 2030

537,000,000

People currently live with diabetes

1,000,000,000+

People will suffer from diabetes by 2050

The unmet opportunity - Pramana's commitment

The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.

100,000,000

People living with Diabetes may be misdiagnosed and affected by Latent Autoimmune Diabetes in Adults right now

The opportunity to treat Latent Autoimmune Diabetes in adults is an area of high unmet medical need associated with Immunometabolic disorders. We are committed to addressing this.